Among the 164 patients included, the heterogeneity in HER2 was identify in 10% of evaluable cases without any pCR among cases classified as heterogeneous, being the Residual Cancer Burden (RCB) III the pathological response more frequent in these patients. The gene discussed is ERBB2; the disease is cancer.